Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
11-19-2021

COVID-19 vaccine hesitancy and attitude toward booster doses
among US healthcare workers
Suman Pal
Rahul Shekhar
Saket Kottewar
Shubhra Upadhyay
Mriganka Singh

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Suman Pal, Rahul Shekhar, Saket Kottewar, Shubhra Upadhyay, Mriganka Singh, Dola Pathak, Devika
Kapuria, Eileen Barrett, and Abu Baker Sheikh

Article

COVID-19 Vaccine Hesitancy and Attitude toward Booster
Doses among US Healthcare Workers
Suman Pal 1 , Rahul Shekhar 1 , Saket Kottewar 2 , Shubhra Upadhyay 1 , Mriganka Singh 3 , Dola Pathak 4 ,
Devika Kapuria 5 , Eileen Barrett 1 and Abu Baker Sheikh 1, *
1

2

3

4

5

*



Citation: Pal, S.; Shekhar, R.;
Kottewar, S.; Upadhyay, S.; Singh, M.;
Pathak, D.; Kapuria, D.; Barrett, E.;
Sheikh, A.B. COVID-19 Vaccine
Hesitancy and Attitude toward
Booster Doses among US Healthcare
Workers. Vaccines 2021, 9, 1358.
https://doi.org/10.3390/
vaccines9111358
Academic Editor: Ralph A. Tripp
Received: 23 August 2021
Accepted: 15 November 2021
Published: 19 November 2021

Publisher’s Note: MDPI stays neutral

Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque,
NM 87106, USA; spal@salud.unm.edu (S.P.); rshekhar@salud.unm.edu (R.S.);
supadhyay@salud.unm.edu (S.U.); ebarrett@salud.unm.edu (E.B.)
Department of Internal Medicine, Division of Hospital Medicine, University of Texas Health San Antonio,
San Antonio, TX 78229, USA; kottewar@uthscsa.edu
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA;
mriganka_singh@brown.edu
Department of Statistics and Probability, Michigan State University, East Lansing, MI 48824, USA;
dpathak@msu.edu
Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110,
USA; devika.kapuria@gmail.com
Correspondence: absheikh@salud.unm.edu; Tel.: +1-631-633-4125

Abstract: Vaccine reluctance among healthcare workers (HCW) can have widespread negative ramifications, including modeling behavior for the general population and challenges with maintaining a
healthy workforce so we can respond to a resurgence of the pandemic. We previously reported that
only one-third of HCW were willing to take the vaccine as soon as it became available prior to its
Emergency Use Authorization (EUA). Here, we re-examine the attitude toward COVID-19 vaccines
among HCW several months after the vaccines have been made widely available. In this study, only
7.9% (n = 107) of respondents were hesitant to take the first or second dose of the vaccine. Younger
age (18–40 years) and lower level of education attainment (GED or less) were associated with higher
vaccine hesitancy, whereas self-identified Asian racial identity was associated with greater acceptance
of COVID-19 vaccination. Among the vaccine-hesitant group, more respondents noted mistrust
of regulatory authorities (45.3%), government (48.6%), and pharmaceutical companies (50%) than
mistrust of doctors (25.4%). Nearly two-thirds of respondents were concerned that vaccination may
be ineffective against new strains and booster doses may be required; however, vaccine-hesitant
respondents’ acceptance of a hypothetical booster dose was only 14.3%. Overall, vaccine hesitancy
was observed to have demographic predictors similar to those previously reported; the hesitancy
of some US HCW to receive booster doses may reflect a general hesitancy to receive other forms of
vaccination.
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The World Health Organization (WHO) declared COVID-19, the disease caused by
SARS-CoV-2, a pandemic on 11 March 2020 [1]. Since then, it has infected over 41 million
individuals and led to more than 666,000 deaths in the US alone [2]. To contain the
pandemic, several vaccine candidates were rapidly developed, rigorously tested, and made
available for use. The Food and Drug Administration (FDA) granted an Emergency Use
Authorization (EUA) to the first COVID-19 vaccine on 11 December 2020 [3]. Since then,
vaccination efforts have been at the forefront of the measures to halt the pandemic and
minimize further loss of lives. However, a low vaccine uptake can be a major barrier to
containing the pandemic.
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Healthcare workers (HCW) are a priority population for vaccination against COVID19. As a high-risk population, HCW were prioritized as one of the first groups to receive
the vaccine in keeping with recommendations by the Advisory Council on Immunization
Practices [4]. HCW are also important sources of medical information and role modeling
for the general population. Therefore, vaccine hesitancy among HCW can have widespread
negative ramifications. We previously reported that, in the months preceding the announcement of EUA for Pfizer-BioNTech COVID-19 vaccine, only one-third of HCW in
the US were willing to take the COVID-19 vaccine as soon as it became available, with a
majority choosing to wait several months before deciding [5]. In this study, we examine
the attitudes and hesitancy of HCW toward COVID-19 vaccines months after they were
made available for use in this population. We also report on the current attitudes of HCW
toward hypothetical additional booster doses of the vaccines.
2. Materials and Methods
Design: We conducted a cross-sectional survey to assess vaccine hesitancy among US
HCW toward COVID-19 vaccination. An online English language survey tool was created
using the REDCap electronic data capture tool hosted at the University of New Mexico.
This survey was modified from our previously published study to gather more pertinent
information regarding vaccine uptake among HCW. All responses were anonymized and
no personally identifying information was collected. The study was conducted according
to the guidelines of the Declaration of Helsinki and approved on 19 September 2020 by the
Institutional Review Board of the University of New Mexico Health Sciences Center (study
ID 20-515).
Sampling: The snowball sampling method was utilized. In this method of sampling,
researchers initially reach out to their networks of contacts to recruit participants; agreeable
participants may then recommend other potential participants from among their respective
networks. This method of sampling was chosen for ease of recruitment with limited
resources, as our populations of interest of HCW in the US were likely to be linked through
professional contacts.
The survey tool was distributed via links emailed to employees of a large academic
medical center in the southwestern US and posted to HCW groups on social media. Data
were collected between 1 February 2021 and 31 March 2021.
Population: All adults (>18 years of age) working in a healthcare setting in the US,
regardless of role or patient contact, were eligible to participate in the study. Informed
consent was obtained prior to enrollment in the study.
3. Outcomes
The main outcome of the study was identification of vaccine hesitancy among HCW
with access to vaccination. Vaccine hesitancy was measured with a set of two questions.
First, we asked respondents whether they had been offered any of the COVID-19 vaccines
currently available in the US. Those who answered in the affirmative were then asked
whether they received the vaccine(s). Their answers were captured as responses to one
of the following questions: “Yes, I already took the first dose and plan to take the second
dose/already taken the second dose”; “Yes I took the first dose but do not plan to take the
second dose”; “No, I will wait to review real-world safety data”; “No I do not plan to take
the vaccine”; and “Not sure”. Those who responded that they received both doses or were
planning to receive both doses of the vaccine were identified as the vaccine non-hesitant
group. Participants who did not accept either dose or responded that they were waiting or
unsure were identified as the vaccine-hesitant group.
The primary analysis was performed by comparing these two groups (vaccine-hesitant
and non-hesitant) to identify factors associated with vaccine hesitancy. The comparison was
based on major demographic predictors: age, gender, race, ethnicity, education, income,
occupation, primary area of work in healthcare (primary medical, primary surgical, etc.),
type of healthcare facility (urban, rural, etc.), political identity, co-morbidity, self-perceived
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risk of contracting COVID-19, and experience of caring for patients with COVID-19. Based
on occupation, the respondents were grouped as either direct medical providers (DMP)
or direct patient-care providers (DPCP). DMP included physicians, resident physicians,
medical students, and advanced-practice providers such as nurse practitioners (NPs)
and physician assistants (PAs). DPCP included RNs, rehabilitation therapists, radiology
technicians, nursing aides, social workers, care coordinators, administrative staff, and
others without direct patient contact.
Respondents’ attitudes toward COVID-19 vaccination in these groups, in terms of
vaccine safety, efficacy, and trust, were assessed via their agreement to statements on a
Likert scale. A descriptive analysis was performed by frequency distribution.
A secondary outcome of the study was an assessment of the attitudes of HCW toward
potential additional booster doses of COVID-19 vaccines. These attitudes were assessed
with a set of two questions. First, we assessed the perception of need for booster doses by
asking, “Are you worried that the current vaccine might not be effective against new strains,
and you might require a booster dose or repeat vaccination?” We then assessed acceptance
of booster doses with the question, “Would you be willing to take the vaccine/booster dose
every year if required for sustained immunity?”.
4. Statistical Methods
Descriptive analyses were conducted on all study variables. Multiple logistic regression models were applied to test for plausible associations of vaccine hesitancy with age,
gender, self-identified racial identity, ethnicity, highest level of educational attainment,
income, occupation, primary area of work in healthcare (primary medical, primary surgical,
etc.), type of healthcare facility (urban, rural etc.), history of taking influenza vaccine,
co-morbidity, self-perceived risk of COVID-19 infection, and experience in taking care of
patients with COVID-19. Each statistical test was conducted at α = 0.05, unless otherwise
indicated. Data analysis was conducted using statistical software R (version 4.0.4).
5. Results
The survey was completed by 1374 respondents. Twelve of the respondents had not
yet been offered the vaccine, and data on vaccine acceptance were unavailable for four
respondents. Therefore, these respondents were excluded from the analysis.
Most of the respondents were between 30 and 60 years of age; female; white; held a
bachelor’s degree or higher level of education; and identified as Democrat (Table 1).
GED: general educational development, indicating high school level of study; DMP:
direct medical providers, including physicians, residents, fellows, medical students, NPs,
PAs, and others; DPCP: direct patient care providers, including nurses, nursing aides,
rehabilitation therapists, and others.
A larger proportion of the respondents reported working in medical specialties as
DMP, and in urban settings. Most participants reported no co-morbid conditions and
perceived themselves to be at risk of slight-to-severe COVID-19 disease. A majority had
directly taken care of COVID-19 patients.
Of the 1358 participants who were offered the vaccine and whose full data were
available, 107 (7.9%) were hesitant to receive either the first or second dose. Of those who
were hesitant, 60 (56.1%) were waiting to review more data, 13 (12.1%) were not sure about
their intention to vaccinate, and 31 (29.0%) did not plan to take the vaccine. Only three
respondents (2.8%) were hesitant to take the second dose after receiving the first dose. All
respondents who had received the first dose and were hesitant to take the second dose
identified side effects with the first dose as the reason.
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Table 1. Demographics of study population.
Variable

Number (n = 1358)

Percentage

170
384
292
294
208

12.5
28.3
21.5
21.6
15.3

1076
273

79.2
20.1

91
43
1132
81

6.7
3.2
83.4
6.0

168
399
250
158
383

12.4
29.4
18.4
11.6
28.2

Hispanic/Latinx

134

9.9

Variable

Number (n = 1358)

Percentage

Not Hispanic/Latinx
Unknown

1185
39

87.3
2.9

542
514
168
134

39.9
37.8
12.4
9.9

826
114
101
317

60.8
8.4
7.4
23.3

835
437
86

61.5
32.2
6.3

729
377
157
95

53.7
27.8
11.6
7.0

Age *
18–30
31–40
41–50
51–60
>60
Gender *
Female
Male
Racial identity *
Asian
Black
White
Other
Education
GED or less
Vocational
Bachelors
Masters
Professional
Ethnicity

Occupation
DMP
DPCP
No direct contact
Administration
Area of work
Medical
Surgical
Diagnostic
Other
Type of facility
Urban
Suburban
Rural
Co-morbidity
None
1
2
3 or more
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Table 1. Cont.
Variable

Number (n = 1358)

Percentage

51

3.8

56

4.1

324
924

23.9
68.0

747
187
423

55.0
13.8
31.1

Self-perceived risk
No, I already have recovered and won’t get re-infected
(diagnosed by a test)
I believe I already had the disease and I am immune to it (not
diagnosed by a test)
No, I am confident I won’t get infected
Yes, I am concerned that I will get infected
COVID contact
Yes, direct contact
Yes, no direct contact
No

* Data missing so that the total of responses in these subgroups was <1358.

Table 2 (and Figure S1) shows the characteristics of the two groups. In a logistic
regression model for hesitancy, significant associations were noted for age, racial identity,
education level, and political affiliation.
Table 2. Comparison of hesitant and non-hesitant groups.
Hesitant Group (Number, percentage)

Non-hesitant Group (Number,
percentage)

20 (18.7)
38 (35.5)
23 (21.5)
18 (16.8)
8 (7.5)

150 (12.0)
346 (27.6)
269 (21.5)
276 (22.1)
200 (16.0)

91 (85.0)
15 (14.0)

985 (78.7)
258 (20.6)

2 (1.9)
6 (5.6)
90 (84.1)
9 (8.4)

89 (7.1)
37 (3.0)
1042 (83.3)
72 (5.8)

GED or less
Vocational
Bachelors
Masters
Professional

25 (23.4)
39 (36.4)
15 (14.0)
12 (11.2)
16 (14.9)

143 (11.4)
360 (28.8)
235 (18.8)
146 (11.7)
367 (29.3)

Variable

Hesitant group (Number, percentage)

Non-hesitant group (number,
percentage)

Hispanic/Latinx

12 (11.2)

122 (9.7)

Not Hispanic/Latinx
Unknown

90 (84.1)
5 (4.7)

1095 (87.5)
34 (2.7)

Variable
Age *
18–30
31–40
41–50
51–60
>60
Gender *
Female
Male
Racial identity *
Asian
Black
White
Other
Education

Ethnicity
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Table 2. Cont.
Occupation
DMP
DPCP
No direct contact
Administration

22 (20.6)
64 (59.8)
6 (5.6)
15 (14.0)

520 (41.6)
450 (36.0)
162 (12.9)
119 (9.5)

66 (61.7)
8 (7.5)
11 (10.3)
22 (20.6)

760 (60.7)
106 (8.5)
90 (7.2)
295 (23.6)

61 (57.0)
36 (33.6)
10 (9.3)

774 (61.9)
401 (32.0)
76 (6.1)

None
1
2

58 (54.2)
25 (23.4)
14 (13.1)

Variable

Hesitant group (Number, percentage)

671 (53.6)
352 (28.1)
143 (11.4)
Non-hesitant group (number,
percentage)

3 or more

10 (9.3)

85 (6.85)

7 (6.5)

44 (3.5)

19 (17.8)

37 (3.0)

15 (14.0)

309 (24.7)

65 (60.7)

859 (68.7)

56 (52.3)
19 (17.8)
32 (29.9)

691 (55.2)
168 (13.4)
391 (31.2)

Area of work
Medical
Surgical
Diagnostic
Other
Type of facility
Urban
Suburban
Rural
Co-morbidity

Self-perceived risk
No, I already have recovered and won’t
get re-infected (diagnosed by a test)
I believe I already had the disease and I
am immune to it (not diagnosed by a test)
No, I am confident I won’t get infected
Yes, I am concerned that I will get
infected
COVID patient contact
Yes, direct contact
Yes, no direct contact
No

* Missing data.

DMP: direct medical providers, including physicians, residents, medical students,
NPs, PAs, and others. DPCP: direct patient care providers, including nurses, nursing aides,
rehabilitation therapists, and others.
Younger age (18–30 years, OR 3.33, CI 1.48–8.23; 31–40 years, OR 2.74, CI 1.32–6.45)
and lower level of education attainment (GED or lower, OR 2.739, CI 1.41–5.48) were
associated with higher vaccine hesitancy. Self-identified Asian racial identity (OR 0.139,
CI 0.02–0.63) was associated with lower levels of vaccine hesitancy.
Lack of trust was more common in the vaccine-hesitant group across all demographic
domains (Figure 1).
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well as among HCW in the US [5,24,25] and globally [15]. Several factors may be responsible
for the variation with age, including higher perceived risk of infection or serious illness,
higher likelihood of presence of medical co-morbidities, and/or higher education, income,
and experience in healthcare settings.
Given the rise in cases of COVID-19 among young adults [26] and reports of complications among young adults [27], vaccine hesitancy could compound these problems.
Accordingly, specific investigation into the causes of vaccine hesitancy is warranted so that
mitigation strategies may be appropriately directed. Consistent with existing literature,
our study confirmed that Asian racial identity was associated with lower vaccine hesitancy [5,15,24,25]. Although previous studies have noted higher vaccine hesitancy among
Black HCW, our current study did not find a statistically significant difference in vaccine
hesitancy between Black and White HCW. While this finding is encouraging, it may be due
to the study being underpowered to detect any difference.
HCW who are hesitant to be vaccinated also state concerns about vaccine safety at
much higher rates compared to non-hesitant HCW. While misinformation about adverse
effects after COVID-19 vaccination has gained traction in segments of social and mass
media, the robust monitoring systems under VAERS (vaccine adverse events reporting
system) have shown very few serious adverse events causally linked to vaccination. Rates
of serious adverse events such as anaphylaxis (2 to 5 people per million vaccinated),
thrombosis with thrombocytopenia syndrome (46 reports after more than 14.5 million
doses of Johnson & Johnson/Janssen vaccine and 2 after more than 362 million doses of
mRNA COVID-19 vaccine), myocarditis, or pericarditis (854 confirmed reports after mRNA
vaccine) are low. Death has been reported in 0.002% of people after COVID-19 vaccination,
although a causal link with COVID-19 vaccine has not been established after review [28].
The data so far show that COVID-19 vaccines are safe; countering misinformation and
disinformation will be key to reducing concerns about vaccine safety and increasing uptake.
HCW who are hesitant to be vaccinated have much higher levels of distrust in information provided by pharmaceutical companies, government, or regulatory authorities
such as the CDC/FDA. Respondents who were hesitant to accept vaccination were more
trusting of vaccination information provided by doctors and healthcare professionals than
by these other sources of information; however, they were less trusting of doctors overall
than were the respondents who were not hesitant to receive the COVID-19 vaccine. A
perception of the beneficial role of healthcare providers has previously been suggested as
a reason for vaccine uptake among children [29]. Thus, individual physicians and other
healthcare professionals may be well suited to providing community messaging about
vaccine acceptance.
Mounting evidence suggests a role for booster doses of COVID-19 vaccine in select
populations. The FDA has issued EUA for the third dose of mRNA vaccines among
solid organ transplant recipients and others who are similarly immunocompromised.
Anticipating that, in the future, the scope for booster doses may broaden, we asked our
respondents about their attitudes toward booster doses of COVID-19 vaccines. Their
responses produced interesting findings. Nearly two-thirds of the respondents in each
group (vaccine-hesitant and non-hesitant) were concerned that current vaccines may have
decreased efficacy against new variants and booster doses may be required. However,
when asked whether they would accept a yearly vaccine against COVID-19 to maintain
immunity, acceptance was widely different between those who had taken the current
vaccine and those who were hesitant to complete current vaccination. We hypothesize that
hesitancy about initial COVID-19 vaccination may be a strong predictor for hesitancy about
booster doses of the vaccine. This is unsurprising, as concerns over vaccine safety and
mistrust of authorities, which were prevalent among hesitant HCW, are likely to extend
to booster doses of the vaccine. Prior refusal of vaccination for other illnesses such as
influenza has also been noted as a predictor of COVID-19 vaccine hesitancy [10,14]. It is
reasonable to assume that this relationship would exist between refusal of initial COVID-19
vaccination and refusal of booster doses. However, it is interesting to note that a similar
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proportion of our respondents in both groups agree on the need for booster doses of the
vaccine. This correlation could indicate that concerns beyond utility are the main drivers of
reluctance to take booster vaccines, and may be an important consideration in the planning
of messaging about booster doses.
This study has limitations. As we utilized snowball sampling, our study population
may not be representative of all US HCW, which limits the generalizability of our findings. The survey questionnaire was available only in an English online format; therefore,
HCW with limited English proficiency and/or with limited internet access may be underrepresented in our study. Social desirability bias may also affect the interpretation of our
study, although the responses were anonymized to minimize this factor.
7. Conclusions
The reluctance of some US HCW to receive COVID-19 vaccination is ongoing and is
more likely to be prevalent among those of younger ages and lower levels of educational
attainment. It is less likely among those with self-identified Asian racial identity. Concerns
about vaccine safety, vaccine efficacy, and lack of trust were possible underlying causes of
vaccine hesitancy. Physicians are more likely than pharmaceutical companies, regulatory
authorities, or government to be trusted sources of information among HCW with COVID19 vaccine hesitancy. Acceptance of COVID-19 vaccine booster doses may mirror a general
hesitancy of some US HCW to receive other types of vaccination.
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